Recurrent hepatitis C after liver transplant

Table 2 Treatment of hepatitis C cirrhosis with triple therapy

Fibrosis stage	Drug	Prior PEG-IFN responsiveness (n)	Treatment response	Serious adverse events1	Ref.
Cirrhosis	Telaprevir	21	62% SVR	9%	[4]
Bridging fibrosis and cirrhosis	Boceprevir	76	47% SVR	12%	[5]
		Relapse (n = 119)	85% SVR
		Partial response (n = 50)	42% SVR
		Null response (n = 88)	24% SVR
Bridging fibrosis and cirrhosis	Boceprevir	Relapse and partial response (n = 63)	56% SVR	12%	[7]
Child A	Telaprevir	285	67% (16 wk)	45%	[8]
	Boceprevir	204	58% (16 wk)	33%

¹Serious adverse event rate for entire study population, % of patients with undetectable hepatitis C virus RNA at 16 wk following drug initiation, an interim analysis. PEG-IFN: Pegylated-interferon; SVR: Sustained viral response rate.